Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Tata Mot 162.55 0.90
Tata Stl 514.00 0.69
State Ba 359.15 0.32
Icici Ba 440.00 0.32
Sun Phar 395.50 0.95
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
 
Sun Pharmaceutical Industries Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
BSE:524715NSE:SUNPHARMABloomberg:SUNP@INReuters:SUN.BO
Market Lot: 1Face Value: 1ISIN Demat: INE044A01036
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
18-Jan-2019
Business Profile
Sun Pharma (SUNPHARMA) is into specialty pharmaceuticals and active pharmaceutical ingredients. The company operates in select therapeutic segments like psychiatry, neurology, cardiology and gastroenterology. As many as eight bulk actives and 18 processes for DMFs have been developed and scaled up. In all, the company has received seven DMFs and nine EDMFs.

The company doubled its capacity and the area at the bulk active site in Panoli. With the completion of this expansion, 269,000 sq. ft. area has been added to the plant thereby offering additional 129 KL reactor capacity for the regulated markets.

The company plans to work on various technologies in NDDS and work on specific therapy areas for NCE. For products that are differentiated for the medium term, it would continue to work on technologically complex products such as liposome delivery systems, microspheres based delivery systems and controlled release technologies.

Financials
The company announced fall of 24.30% in consolidated net profit on y-o-y basis to Rs 13.09 billion, while total income fell 100.00% y-o-y basis to Rs 0.00 million for the quarter ended March 2018.

Recent Developments
03-DEC-18
Sun Pharmaceutical Industries, today announced that Sun Pharma has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Ganirelix Acetate Injection, 250 mcg/0.5 mL.

28-NOV-18
Sun Pharmaceutical Industries announced that Sun Pharma has entered into a definitive agreement to acquire Pola Pharma Inc. (Pola Pharma), a Japanese pharmaceutical company engaged in research

24-OCT-18
Sun Pharmaceutical Industries announced that moderate-to-severe psoriasis treatment ILUMYATM (tildrakizumab-asmn) 100 mg/mL is now available in the United States. ILUMYATM is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

21-SEP-18
Sun Pharmaceutical Industries today announced that Sun Pharma has received the Australian Therapeutic Goods Administration (TGA) approval for its speciality product, ILUMYA??? (tildrakizumab) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

18-SEP-18
Sun Pharmaceutical Industries today announced that Almirall has received the European Commission (EC) approval for ILUMETRI (tildrakizumab) for the treatment of adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy.

14-SEP-18
Sun Pharmaceutical Industries today announced U.S. Food and Drug Administration (USFDA) approval for the New Drug Application (NDA) of XELPROSTM (latanoprost ophthalmic emulsion) 0.005% for the reduction of elevated intraocular pressure (IOP, or pressure inside the eye)

11-SEP-18
Sun Pharmaceuticals Industries announced that one of the wholly owned subsidiaries of the company has agreed to acquire shares of Tarsius Pharma, ('Tarsius'), Israel, by way of subscription of 345,622 ordinary shares of nominal value of NIS 0.01 each, representing 18.75% of shares of Tarsius, on a fully diluted basis.

16-AUG-18
Sun Pharmaceutical Industries has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration (FDA). CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).



In Brief

 
Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer